100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes 100% increase in SCr at final compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ temporary or permanent… compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ infection ( · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in adverse events ‐ infection ( compared with alkylating agents ± steroids (low certainty).
1 finding from 1 review
Malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy (range 30 to 36 months compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Early graft thrombosis · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Major bleeding events: unfractionated heparin · kidney transplant recipients
Heparin showed no clear difference in major bleeding events: unfractionated heparin compared with placebo (low certainty).
1 finding from 1 review
Major bleeding events: all heparin · kidney transplant recipients
Heparin showed no clear difference in major bleeding events: all heparin compared with placebo (low certainty).
1 finding from 1 review
Readmissions to intensive care: all heparin · kidney transplant recipients
It is very uncertain whether heparin changes readmissions to intensive care: all heparin compared with placebo (very low certainty).
1 finding from 1 review
Blood transfusion requirements · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Graft and patient survival · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐graft thrombosis · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether antibiotics changes incidence of HUS compared with no treatment (very low certainty).
1 finding from 1 review
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether synsorb Pk changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for acute dialysis · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological complications · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review